Related Experiment Videos
Serum interleukin-1 beta levels correlate with neoplastic bulk in hairy cell leukemia
1Dipartimento di Biopatologia Umana, Universitá La Sapienza, Rome, Italy.
Insights
Interleukin-1 beta and soluble IL-2 receptor serum levels are elevated in hairy cell leukemia (HCL) patients, particularly at diagnosis or relapse. Elevated IL-1 beta correlates with disease burden and may serve as a specific HCL marker.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Hairy cell leukemia (HCL) is a rare B-cell chronic lymphoid leukemia.
- Cytokine dysregulation is implicated in the pathogenesis of various hematological malignancies.
Purpose of the Study:
- To investigate serum levels of Interleukin-1 alpha (IL-1 alpha), Interleukin-1 beta (IL-1 beta), and soluble IL-2 receptor (sIL-2R) in HCL patients.
- To assess the correlation of these markers with disease status and infiltration.
Main Methods:
- Serum samples from 24 HCL patients and controls were analyzed.
- IL-1 alpha, IL-1 beta, and sIL-2R levels were measured using specific assays.
- Patient groups included those at diagnosis, relapse, partial response, and complete response.
Main Results:
- HCL patients exhibited significantly higher serum levels of IL-1 beta and sIL-2R compared to controls.
- IL-1 alpha levels did not differ significantly between HCL patients and controls.
- Elevated IL-1 beta and sIL-2R were observed in patients at diagnosis or relapse versus those in remission.
- IL-1 beta levels correlated directly with sIL-2R and bone marrow infiltration (HC index).
- HCL patients showed the highest IL-1 beta increase compared to other leukemia and lymphoma types.
Conclusions:
- Serum IL-1 beta and sIL-2R are significantly elevated in HCL patients.
- These markers are particularly increased in active disease states (diagnosis and relapse).
- IL-1 beta shows potential as a specific clinical marker for HCL due to its strong correlation with disease burden and specificity across hematological malignancies.
Abstract:
Interleukin-1 alpha (IL-1 alpha), interleukin-1 beta (IL-1 beta) and soluble IL-2 receptor (sIL-2R) serum levels were evaluated in 24 hairy cell leukemia (HCL) patients. Of these, three patients were studied at the time of diagnosis, 12 in relapse after interferon (IFN) therapy, eight with a partial response after IFN and one with a complete response after 2-deoxycoformycin (DCF) therapy. Statistically significant differences were observed in the serum levels of IL-1 beta and sIL-2R between HCL patients and controls. These were 400.3 pg per 0.1 ml (range 23.2-990) and 64.3 pg per 0.1 ml (20-115) for IL-1 beta and 4667.2 U/ml (488-7800) and 424.3 U/ml (188-666) for sIL-2R, respectively. In contrast, IL-1 alpha measurements showed no statistical differences between the two groups. A significant increase of sIL-2R (p = 0.01) and IL-1 beta (p = 0.03) serum levels was observed in patients studied at the time of diagnosis or in relapse compared to those in partial or complete remission. IL-1 beta serum levels directly correlated with sIL-2R (p less than 0.0001) and with hairy cell (HC) bone marrow infiltration, expressed by the HC index (p = 0.003). The comparison of IL-1 beta serum levels of HCL patients with those detected among 149 patients grouped according to diagnosis (Hodgkin's disease = 17, non-Hodgkin's lymphomas = 57, acute non-lymphoid leukemia = 46, and acute lymphoid leukemia = 29) indicate that HCL patients showed the highest IL-1 beta serum level increase, indicating that IL-1 beta could be used as a specific clinical marker of this disease.